Filgrastim

證據等級: L5

預測適應症: 10 個

Filgrastim: From Neutropenia/Stem Cell Mobilization to Primary Release Disorder of Platelets

One-Sentence Summary

Filgrastim (recombinant human G-CSF) is a hematopoietic growth factor whose established clinical use is treating chemotherapy-induced neutropenia and mobilizing peripheral blood stem cells before collection. The TxGNN model predicts it may be effective for Primary Release Disorder of Platelets, but the supporting evidence is weak: of 14 clinical trials surfaced, most are graded as not directly relevant (off-target stem cell transplant studies), and only 1 publication (an observational cohort study, relevance still pending review) touches the topic.

Quick Overview

Item	Content
Original Indication	Neutropenia (chemotherapy-induced) / Peripheral blood stem cell mobilization — based on the drug's known G-CSF mechanism described in the evidence pack's rationale field; not an officially approved Taiwan indication (see Market Status)
Predicted New Indication	Primary release disorder of platelets
TxGNN Prediction Score	99.998% (rank 48)
Evidence Level	L4 (mechanistic/indirect only — no clinical trial or study directly targets this indication)
Taiwan Market Status	Not marketed (未上市)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Filgrastim is recombinant human granulocyte colony-stimulating factor (G-CSF). It acts on granulocyte precursor cells to promote proliferation and differentiation, and it mobilizes hematopoietic stem cells from the bone marrow into peripheral blood — the basis for its established uses in neutropenia management and stem cell collection prior to transplantation.

Primary release disorder of platelets (a δ-storage pool disease affecting platelet granule release) has no established pharmacological link to G-CSF signaling. The evidence pack's own mechanistic assessment is explicit on this point: there is "no known direct pharmacological mechanism" connecting filgrastim to platelet granule release function. The single related publication describes an indirect observation — that G-CSF mobilization in healthy stem cell donors preferentially affects lymphocyte subsets — which is not a treatment mechanism study for platelet release disorders.

In short, the high TxGNN score appears to be driven by semantic/graph clustering around "hematopoietic" and "hemorrhagic disorder" concepts rather than a validated pharmacological pathway. This is consistent with the model's other top candidates for filgrastim (pseudo-von Willebrand disease, Glanzmann thrombasthenia, Scott syndrome, and others), all of which the evidence pack itself flags as having no mechanistic overlap with G-CSF signaling and no supporting trial or literature evidence (Evidence Level L5, Hold recommendation for every one of them).

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00281879	Phase 2	Terminated	200	Unrelated donor stem cell transplant for hematologic malignancies — not relevant (grade C: population and endpoint are hematologic cancer, not platelet release disorder)
NCT00043979	Phase 2	Completed	60	Allogeneic/syngeneic stem cell transplant in pediatric sarcomas — not relevant (grade C)
NCT00354172	Phase 2	Terminated	16	Umbilical cord blood transplant for myeloid leukemia — not relevant (grade C)
NCT00923364	Phase 2	Completed	19	Reduced-intensity stem cell transplant for GATA2 mutation patients — relevance not yet graded
NCT02646098	Phase 2	Completed	64	CD34+ selected vs unselected autologous transplant in lymphoma — not relevant (grade C)
NCT05436418	Phase 1/2	Recruiting	260	Post-transplant cyclophosphamide dosing for GVHD prophylaxis — not relevant (grade C)
NCT05170828	Phase 1	Withdrawn	0	Cryopreserved unrelated donor bone marrow transplant — relevance not yet graded
NCT00076752	Phase 2	Completed	9	Autologous stem cell transplant for severe lupus (SLE) — relevance not yet graded
NCT04540120	Phase 2	Terminated	49	Dapansutrile for COVID-19 cytokine release syndrome — relevance not yet graded
NCT06859424	Phase 2	Recruiting	358	Post-transplant cyclophosphamide GVHD prophylaxis platform trial — relevance not yet graded

Note: 4 additional trials were returned but omitted for brevity; none were graded as directly relevant to this indication. Across all 14 trials retrieved, none study filgrastim as a treatment for a platelet release disorder — all involve hematopoietic stem cell transplantation for unrelated hematologic malignancies or autoimmune disease.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
29770133	2018	Cohort/Observational	Frontiers in Immunology	G-CSF mobilization in healthy stem cell donors preferentially mobilizes lymphocyte subsets; an indirect immunological observation, not a study of platelet release function or treatment efficacy (relevance grading still pending)

Taiwan Market Information

Filgrastim is not currently marketed in Taiwan — no authorization records are available in the evidence pack (0 licenses).

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug interaction data are all flagged as data gaps in this evidence pack — including a Blocking-severity gap on the TFDA package insert, which prevents a preliminary safety assessment.)

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic link between G-CSF signaling and platelet release/granule disorders is unestablished — the evidence pack's own rationale states there is no known direct pharmacology connecting the two. No clinical trial or publication actually studies filgrastim for this indication; the trials retrieved are almost entirely off-target hematopoietic stem cell transplant studies, and the single literature hit is an indirect observational finding. This same weak-evidence pattern (Evidence Level L5, Hold) applies to all nine other TxGNN-predicted indications for filgrastim in this pack (pseudo-von Willebrand disease, Glanzmann thrombasthenia, Scott syndrome, C1 inhibitor deficiency, and others), none of which have any supporting trial or literature evidence at all.

To proceed, the following is needed:

TFDA package insert warnings/contraindications (Blocking data gap — required before any S1 safety review can begin)
Mechanism of action documentation (High-severity data gap — needed to properly evaluate mechanistic plausibility)
A dedicated preclinical or mechanistic study directly linking G-CSF/granulocyte pathways to platelet granule release function
If pursued, a hematology/coagulation specialist review of biological plausibility before any trial design work
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.